Shoppers Drug Mart reports 1.7 million consultations and Loblaw stock costs EUR 43.40

Published on 10/28/2026 at 11:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Shoppers Drug Mart reported 1.7 million consultations in 2025. Loblaw stock costs EUR 43.40 on October 28, 2026, while 85 percent of appointments were booked promptly.

Pharmacy report broadens Loblaw context

Shoppers Drug Mart reported 1.7 million minor ailment consultations and treatments for 2025.
More than 85 percent of minor ailment appointments in 2025 were booked for the same or next day.
Loblaw stock traded at EUR 43.40 at 11:10 a.m. CEST at Lang & Schwarz on October 28, 2026.

Loblaw, CA5394811015, Illustration mit AI erstellt.

Loblaw Companies Limited (ISIN CA5394811015) is adding fresh evidence to its pharmacy strategy: Shoppers Drug Mart reported 1.7 million consultations and treatments for minor ailments in 2025. The Loblaw report also said more than 85 percent of minor ailment assessment appointments were booked for the same or next day.

Pharmacy data adds operating detail

The report, released on October 26, 2026, gives investors a more specific measure of the health division's activity than a general store-count update. It covers Shoppers Drug Mart, an independent operating division of Loblaw Companies Limited, and describes pharmacy-led services as part of the wider Canadian healthcare system.

The report also cited a 2026 operating figure: more than one-third of services provided in Pharmacy Care Clinics were delivered outside regular weekday hours, including evenings, weekends and holidays. That figure points to access and service availability as part of the division's operating proposition.

What does the report quantify?

Several patient-outcome measures extend beyond activity volumes. The company said 95 percent of Ontario patients receiving a minor ailment assessment for a urinary tract infection reported that symptoms had resolved or were improving during pharmacist follow-up calls. In Alberta, one in nine patients receiving a Heart Health Assessment had A1c levels potentially indicating prediabetes or diabetes.

The report also said two in three Ontario patients with severe diabetes who received a medication review achieved a clinically significant reduction in A1c levels within a year. These figures describe reported patient outcomes, not Loblaw's consolidated financial performance, but they provide a measurable view of the pharmacy platform's reach.

Next company date

Loblaw's next stated reporting date is November 19, 2026, when the company is scheduled to publish its third-quarter results. The report released on October 26 therefore arrives before the next financial checkpoint and adds operational context for the pharmacy division.

Stock remains at the market center

Loblaw stock was trading at EUR 43.40 at Lang & Schwarz on October 28, 2026, at 11:10 a.m. CEST. The quote is presented separately from the company's Canadian operating figures because the health report does not provide a stock-price assessment.

The further course of trading is shown by the continuously updated real-time quote of Loblaw stock.